The company follows the January to December financial year.
EBITDA rose 38.5% to ₹88.8 crore in the March quarter, compared with ₹64.1 crore in the corresponding period last year. EBITDA margin stood at 38.7% versus 37.1% in the same quarter last year.
Also Read: Sanofi Consumer Healthcare declares ₹55 final dividend even as Q4 profit drops 35%, margins shrink
For the quarter ended March 31, 2026, domestic sales grew by 15.5%, aided by the relaunch, and export sales grew by 144.4% on a lower base as compared to the quarter ended March 31, 2025.
Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Ltd, said, “Our performance this quarter reflects consistent, disciplined execution across our key markets.
Domestic business outpaced the market, delivering both market share gains and volume growth, while exports made a meaningful contribution to overall results. Guided by science and driven by purpose, we remain committed to simplifying self‑care and making it more accessible and effective for consumers.”
Also Read: Sanofi to sell 50% of Opella in $17 billion deal with CD&R, job guarantees for France included
Shares of Sanofi Consumer Healthcare India Ltd ended at ₹4,708.10, up by ₹60.65, or 1.31%, on the BSE.
(Edited by : Jomy Jos Pullokaran)
First Published: Apr 28, 2026 4:51 PM IST
